Literature DB >> 29214407

Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015.

Naoki Nakagawa1, Naoyuki Hasebe2, Motoshi Hattori3, Michio Nagata4, Hitoshi Yokoyama5, Hiroshi Sato6, Hitoshi Sugiyama7, Akira Shimizu8, Yoshitaka Isaka9, Shoichi Maruyama10, Ichiei Narita11.   

Abstract

BACKGROUND: The incidence and age distribution of membranoproliferative glomerulonephritis (MPGN) vary throughout the world by race and ethnicity. We sought to evaluate the clinical features, pathogenesis, and age distribution of MPGN among a large nationwide data from the Japan Renal Biopsy Registry (J-RBR).
METHODS: A cross-sectional survey of 593 patients with MPGN (types I and III) registered in the J-RBR between 2007 and 2015 was conducted. Clinical parameters, and laboratory findings at diagnosis were compared between children (< 20 years), adults (20-64 years), and elderly patients (≥ 65 years).
RESULTS: The median age of the patients was 59.0 years and mean proteinuria was 3.7 g/day. The rate of nephrotic syndrome was significantly higher in adults (40.4%) and elderly patients (54.0%) than in children (14.9%), whereas the rate of chronic glomerulonephritis was significantly higher in children (66.2%) than in adults (34.4%) and elderly patients (31.2%). According to the CGA risk classification, high-risk (red zone) cases accounted for 3.4% of children, 52.5% of adults and 84.1% of elderly patients with MPGN. As for pathogenesis, primary MPGN was most frequent (56.0%). Lupus nephritis was the most common disease among adult patients with secondary MPGN, whereas infectious disease was more common in elderly patients. Multiple regression analysis revealed that high systolic blood pressure and high proteinuria were independent factors associated with decreased estimated glomerular filtration rate (eGFR) in adults and elderly patients with MPGN.
CONCLUSIONS: In Japan, adults and elderly patients with MPGN had a lower eGFR and severer proteinuria than children.

Entities:  

Keywords:  Age distribution; Membranoproliferative glomerulonephritis; Registry; Renal pathology

Mesh:

Year:  2017        PMID: 29214407     DOI: 10.1007/s10157-017-1513-7

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  24 in total

1.  Membranous nephropathy in Japan: analysis of the Japan Renal Biopsy Registry (J-RBR).

Authors:  Hitoshi Yokoyama; Takashi Taguchi; Hitoshi Sugiyama; Hiroshi Sato
Journal:  Clin Exp Nephrol       Date:  2012-02-23       Impact factor: 2.801

Review 2.  Membranoproliferative glomerulonephritis--a new look at an old entity.

Authors:  Sanjeev Sethi; Fernando C Fervenza
Journal:  N Engl J Med       Date:  2012-03-22       Impact factor: 91.245

3.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

Review 4.  Update on membranoproliferative GN.

Authors:  Naveed Masani; Kenar D Jhaveri; Steven Fishbane
Journal:  Clin J Am Soc Nephrol       Date:  2014-01-09       Impact factor: 8.237

5.  A clinical evaluation of renal amyloidosis in the Japan renal biopsy registry: a cross-sectional study.

Authors:  Shinichi Nishi; Eri Muso; Akira Shimizu; Hitoshi Sugiyama; Hitoshi Yokoyama; Yukio Ando; Shunsuke Goto; Hideki Fujii
Journal:  Clin Exp Nephrol       Date:  2016-08-25       Impact factor: 2.801

6.  Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study.

Authors:  Sundararaman Swaminathan; Nelson Leung; Donna J Lager; L Joseph Melton; Eric J Bergstralh; Audrey Rohlinger; Fernando C Fervenza
Journal:  Clin J Am Soc Nephrol       Date:  2006-04-19       Impact factor: 8.237

7.  Revised equations for estimated GFR from serum creatinine in Japan.

Authors:  Seiichi Matsuo; Enyu Imai; Masaru Horio; Yoshinari Yasuda; Kimio Tomita; Kosaku Nitta; Kunihiro Yamagata; Yasuhiko Tomino; Hitoshi Yokoyama; Akira Hishida
Journal:  Am J Kidney Dis       Date:  2009-04-01       Impact factor: 8.860

Review 8.  C3 glomerulopathy and current dilemmas.

Authors:  Naoko Ito; Ryuji Ohashi; Michio Nagata
Journal:  Clin Exp Nephrol       Date:  2016-11-23       Impact factor: 2.801

9.  Clinical manifestations of Henoch-Schönlein purpura nephritis and IgA nephropathy: comparative analysis of data from the Japan Renal Biopsy Registry (J-RBR).

Authors:  Hiroyuki Komatsu; Shouichi Fujimoto; Norishige Yoshikawa; Hiroshi Kitamura; Hitoshi Sugiyama; Hitoshi Yokoyama
Journal:  Clin Exp Nephrol       Date:  2015-10-11       Impact factor: 2.801

10.  Drug-induced kidney disease: a study of the Japan Renal Biopsy Registry from 2007 to 2015.

Authors:  Hitoshi Yokoyama; Ichie Narita; Hitoshi Sugiyama; Michio Nagata; Hiroshi Sato; Yoshihiko Ueda; Seiichi Matsuo
Journal:  Clin Exp Nephrol       Date:  2015-11-21       Impact factor: 2.801

View more
  8 in total

1.  Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center.

Authors:  Marie Nakano; Kazunori Karasawa; Takahito Moriyama; Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2019-03-11       Impact factor: 2.801

2.  Effectiveness of cryofiltration and mizoribine combination with oral steroid therapy in a patient with membranoproliferative glomerulonephritis due to essential cryoglobulinemia.

Authors:  Yuka Kurokawa; Kiyomi Koike; Yusuke Kaida; Sakuya Ito; Hirotane Chiba; Kengo Urae; Tomofumi Moriyama; Nao Nakamura; Tetsurou Imai; Ryo Shibata; Takuma Hazama; Daisuke Wakasugi; Seiya Okuda; Kei Fukami
Journal:  CEN Case Rep       Date:  2019-03-29

3.  Long-Term Outcomes of C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis in Children.

Authors:  Amrit Kirpalani; Natasha Jawa; William E Smoyer; Christoph Licht
Journal:  Kidney Int Rep       Date:  2020-10-03

4.  Clinical and pathological analysis of renal biopsies of elderly patients in Northeast China: a single-center study.

Authors:  Ping Nie; Yan Lou; Yali Wang; Xue Bai; Li Zhang; Shan Jiang; Bing Li; Ping Luo
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

5.  Characteristics and outcomes of glomerulonephritis with membranoproliferative pattern in children.

Authors:  Linan Xu; Fengfang Wei; Jiayan Feng; Jiaojiao Liu; Jialu Liu; Xiaoshan Tang; Xiaoyan Fang; Jing Chen; Yihui Zhai; Haimei Liu; Li Sun; Yanyan Qian; Bingbing Wu; Huijun Wang; Qian Shen; Jia Rao; Hong Xu
Journal:  Transl Pediatr       Date:  2021-11

6.  Role of Direct Immunofluorescence Microscopy in Spectrum of Diffuse Proliferative Glomerulonephritis: A Single-Center Study.

Authors:  Sonal Jain; Shivangi Chauhan; Sonali Dixit; Neha Garg; Sonal Sharma
Journal:  J Microsc Ultrastruct       Date:  2021-02-09

7.  Long-term outcomes of patients with end-stage kidney disease due to membranoproliferative glomerulonephritis: an ANZDATA registry study.

Authors:  Gregory J Wilson; Yeoungjee Cho; Armando Teixiera-Pinto; Nicole Isbel; Scott Campbell; Carmel Hawley; David W Johnson
Journal:  BMC Nephrol       Date:  2019-11-21       Impact factor: 2.388

8.  The revised version 2018 of the nationwide web-based registry system for kidney diseases in Japan: Japan Renal Biopsy Registry and Japan Kidney Disease Registry.

Authors:  Takaya Ozeki; Shoichi Maruyama; Michio Nagata; Akira Shimizu; Hitoshi Sugiyama; Hiroshi Sato; Hitoshi Yokoyama
Journal:  Clin Exp Nephrol       Date:  2020-08-06       Impact factor: 2.801

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.